False-positive rates rose from 0.3% below age 60 to 7.5% at 80 or older in an analysis of whole-blood samples.False-positive rates rose from 0.3% below age 60 to 7.5% at 80 or older in an analysis of whole-blood samples.
Higher intake was associated with more new blood cancer diagnoses among 204,494 UK Biobank participants followed for a median 10.5 years.Higher intake was associated with more new blood cancer diagnoses among 204,494 UK Biobank participants followed for a median 10.5 years.
Who was studied204,494 UK Biobank participants without hospital-recorded myeloid neoplasms
What changedMyeloid blood cancer diagnosis rates were higher with higher ultra-processed food intake (hazard ratio 1.12 per standard-deviation increase)
The catchHospital inpatient records could miss myeloid cancers managed entirely in outpatient care
Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.
Serial blood samples revealed carboplatin and PARP inhibitors expand DNA damage response clones, though germline homologous recombination deficiency reduces this growth.Serial blood samples revealed carboplatin and PARP inhibitors expand DNA damage response clones, though germline homologous recombination deficiency reduces this growth.
Median growth of mutated blood-cell groups was 0.016 per year lower with vitamin C than placebo, but the results were consistent with no difference.Median growth of mutated blood-cell groups was 0.016 per year lower with vitamin C than placebo, but the results were consistent with no difference.
Bone marrow samples from 10 people treated weekly for at least a year revealed parallel inflammatory and anti-inflammatory programs.Bone marrow samples from 10 people treated weekly for at least a year revealed parallel inflammatory and anti-inflammatory programs.
Who was studied10 patients with myeloproliferative neoplasms, against pretreatment samples
What changedInterferon increased lymphoid and inflammatory myeloid precursors and reduced platelet and red-cell precursors compared with pretreatment samples
The catchSerial single-cell profiling included only 10 individuals